PFE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Pfizer Inc (PFE) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock lacks significant positive momentum, and its financial performance has been weak. While the stock has a high dividend yield and some analysts are optimistic about its long-term potential, the near-term outlook is clouded by structural headwinds and limited catalysts.
The technical indicators suggest a neutral trend. The MACD histogram is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 46.475, and moving averages are converging, showing no clear trend. Key support is at 26.81, and resistance is at 28.388.
Some analysts have raised price targets recently, and there is optimism about Pfizer's GLP-1 pipeline and oncology programs. The company also has a high dividend yield, which could attract income-focused investors.
Additionally, Pfizer faces a $15B-$20B revenue cliff through 2030, with limited near-term pipeline visibility. The stock has also declined by 29% over the past five years, reflecting market concerns about growth potential.
In Q4 2025, revenue dropped by -1.16% YoY to $17.56 billion. Net income plunged by -501.95% YoY to -$1.65 billion, and EPS fell by -514.29% YoY to -$0.29. However, gross margin increased by 6% YoY to 64.15%.
Analyst ratings are mixed. Recent upgrades include Argus upgrading to Buy with a $35 price target, citing long-term growth potential. However, RBC Capital initiated coverage with an Underperform rating and a $25 price target, citing structural headwinds and limited near-term catalysts.
